Cervical cancer: incidence and survival in migrants within Spain

This study examined the incidence of cervical cancer and survival rates according to migrant experience of women from different regions of Spain to Girona, Catalonia (Spain). DESIGN--Using data from the population based cancer registry of Girona for the period 1980-89, crude and age adjusted incidence rates were calculated for local-born and first generation migrants from other Spanish regions. The age standardised rate ratio (SRR) was calculated and Cox's regression model was used to adjust survival according to migrant status for age and stage at diagnosis. MAIN RESULTS--The incidence of cervical cancer was significantly higher in first generation Spanish migrants compared with locally born women (SRR: 2.02; 95% CI 1.40:2.92). The stage at diagnosis was more advanced among migrants. Survival probability was significantly associated with stage at diagnosis, but age and region of birth were not. CONCLUSIONS--Migrants from the southern Spanish regions show a twofold excess in the incidence of cervical cancer compared with the Girona-born female population. Cases of cervical cancer in migrants are diagnosed at a more advanced stage and as a consequence have a poorer prognosis.

HPV & head and neck cancer: a descriptive update

The incidence of head and neck squamous cell carcinoma (HNSCC) has been gradually increasing over the last three decades. Recent data have now attributed a viral aetiology to a subset of head and neck cancers. Several studies indicate that oral human papillomavirus (HPV) infection is likely to be sexually acquired. The dominance of HPV 16 in HPV+ HNSCC is even greater than that seen in cervical carcinoma of total worldwide cases. Strong evidence suggests that HPV+ status is an important prognostic factor associated with a favourable outcome in head and neck cancers. Approximately 30 to 40% of HNSCC patients with present with early stage I/II disease. These patients are treated with curative intent using single modality treatments either radiation or surgery alone. A non-operative approach is favored for patients in which surgery followed by either radiation alone or radiochemotherapy may lead to severe functional impairment. Cetuximab, a humanized mouse anti-EGFR IgG1 monoclonal antibody, improved locoregional control and overall survival in combination with radiotherapy in locally advanced tumours but at the cost of some increased cardiac morbidity and mortality. Finally, the improved prognosis and treatment responses to chemotherapy and radiotherapy by HPV+ tumours may suggest that HPV status detection is required to better plan and individualize patient treatment regimes.

Bases per crear un tractament de prevenció secundaria per pacients amb fuetada cervical

Projecte de recerca elaborat a partir d’una estada al departament d’anestesiologia de la University of Washington durant juliol i agost del 2006. La fuetada cervical és una lesió molt freqüent. Encara que els problemes associats es resolen en un període de temps curt en la majoria de casos, un percentatge de casos que oscil·la entre el 12 i el 42% desenvolupa dolor cervical crònic i discapacitat associada. Aquesta situació provoca un elevat cost econòmic per a la societat i un elevat patiment per a les persones que pateixen dolor crònic cervical i discapacitat com a conseqüència de la fuetada cervical. Ambdues conseqüències podrien ser evitades dissenyant estratègies de prevenció secundaria efectives. Aquest és precisament l’objectiu de la tesis del doctorant Aquesta va ser considerada essencial perquè en aquesta universitat esta l’únic grup de recerca que esta realitzant un tractament de prevenció secundaria per a pacients amb fuetada cervical. La realització de totes aquestes tasques ha permès al doctorant millorar el seu treball de recerca i començar a dissenyar un programa de prevenció secundaria per a la nostra població de pacients amb fuetada cervical. A més, s’han establert lligams de col·laboració.